Moberg Pharma Secures First US Patent on Improved MOB-015 Dosing Through 2041

Moberg Pharma said on November 3, 2026 that the United States Patent and Trademark Office granted a patent covering an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry date in December 2041. The Swedish company announced the grant through PR Newswire.

What the MOB-015 Dosing Patent Covers

The US is the first market to grant a patent application relating to the improved dosing of MOB-015. Moberg Pharma said the patent rests on a combination of clinical results, including studies supporting the European approval of MOB-015 and its most recently completed Phase 3 study in North America. Patent applications on MOB-015 dosing have also been filed in other markets and remain under examination.

Moberg Pharma holds all rights to MOB-015 in the US, which it describes as the largest single onychomycosis market globally. The company said its ambition is to run an additional Phase 3 study to support a future FDA approval. "We are very pleased that the first patent relating to the improved dosing of MOB-015 has now been granted in the U.S.," said Anna Ljung, CEO of Moberg Pharma. "As we evaluate the optimal development and partnership strategy for the U.S., strengthening the intellectual property position around MOB-015 is an important part of creating long-term value from the asset."

MOB-015 is approved in 14 countries and is marketed as Terclara in Sweden and Norway, where Moberg Pharma says it is the market leader. The company is preparing a broader international rollout, including launches with Karo Healthcare under the Lamisil brand.

Terclara's Israel Launch and Launch Preparations

Moberg Pharma launched Terclara (MOB-015) in Israel, with Padagis Israel Agencies promoting it to dermatologists, news.cision.com reported on September 23, 2026. The launch followed regulatory clearance of the first commercial batch and made Israel the first non-Nordic market.

On June 15, 2026, news.cision.com reported that European countries approved rebranding of MOB-015 (Terclara) to Karo Healthcare's brand, with first deliveries planned around year-end and first patients in Israel expected in the third quarter of 2026. On September 28, 2026, news.cision.com reported that Moberg Pharma would attend the EADV and CPHI conferences in Vienna and Milan in September and October 2026 to engage with experts ahead of the broader international rollout.

Patent Moves at MAXONA and Galderma

MAXONA Pharmaceuticals received a USPTO notice of allowance for its patent application on using nefopam to treat pruritus, expecting final issuance by year-end, PR Newswire reported on October 27, 2026. MAXONA also began preclinical work on MAX-425 for chronic pruritus of unknown origin.

An ICC arbitral tribunal confirmed the termination of Galderma's 2014 neuromodulator research and development partnership with Ipsen, AETOSWire reported on October 21, 2026. Galderma said the decision does not affect its commercialization of Dysport, Alluzience and Relfydess.

Moberg Pharma's Next Steps

Moberg Pharma's Nomination Committee, appointed on October 20, 2026, will submit proposals to the 2026 AGM on May 20, 2027, news.cision.com reported. The company said it remains focused in the near term on markets where MOB-015 is already approved or where commercial partnerships are in place.